Biotech Hubs 2026: The Best Cities for Biotech Startups

Biotech Ecosystem Comparison

Biotech Hubs in the USA: The Complete List

The major biotech hubs in the USA are Boston–Cambridge, the San Francisco Bay Area, San Diego, and North Carolina's Research Triangle — together they attract the large majority of US life sciences venture funding. A second tier of fast-growing hubs, led by Philadelphia, Seattle, and the New York/New Jersey corridor, offers strong research institutions with meaningfully lower lab-space and talent costs.

1. 1
   Boston–Cambridge, MA — The world’s largest biotech cluster — Kendall Square, MIT/Harvard, and the deepest pool of biotech capital and talent.
2. 2
   San Francisco Bay Area, CA — Genentech’s birthplace; strongest overlap of tech, AI-driven drug discovery, and venture capital.
3. 3
   San Diego, CA — Genomics and diagnostics powerhouse (Illumina, Scripps, UCSD) at lower cost than SF or Boston.
4. 4
   Research Triangle, NC — Duke, UNC, and NC State feed a growing cluster with major pharma manufacturing nearby.
5. 5
   New York / New Jersey — Big-pharma headquarters density, growing NYC lab space, and unmatched access to capital markets.
6. 6
   Philadelphia, PA — The leading US hub for cell and gene therapy, anchored by Penn and CHOP.
7. 7
   Seattle, WA — Immunotherapy and computational biology strength via Fred Hutch and UW.
8. 8
   Los Angeles / Orange County, CA — Large clinical-trial population, Caltech/UCLA research, and medtech depth.
9. 9
   Chicago, IL — Emerging hub with strong university pipelines and lower operating costs.
10. 10
    Houston, TX — Texas Medical Center — the world’s largest medical complex — plus aggressive state incentives.

Emerging biotech hubs to watch in 2026

Beyond the big four, the fastest-rising biotech hubs are Philadelphia (cell and gene therapy, anchored by Penn and CHOP), Seattle (immunotherapy and computational biology via Fred Hutch and UW), Houston (the Texas Medical Center plus state incentives), Chicago (strong university pipelines at lower operating cost) and Los Angeles / Orange County (clinical-trial access and medtech depth). They trade some capital density for cheaper lab space and talent, which matters most for seed-stage companies watching their burn.